Document:

Exhibit
10.7

 

AMENDMENT
TO 

SECURITIES
PURCHASE AGREEMENT

 

THIS
AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”) is made as of February 10, 2016 (the “Effective
Date”) by and among Guided Therapeutics, Inc., a Delaware corporation (the “Company”), and Aquarius
Opportunity Fund (the “Lead Purchaser”), and amends that certain Securities Purchase Agreement, dated as of
June 29, 2015, by and among the Company, the Lead Purchaser, and certain other Purchasers identified therein (the “Other
Purchasers”), as amended by that certain Interim Securities Purchase Agreement, dated as of September 3, 2015 (collectively,
the “Purchase Agreement”). Capitalized terms used herein without definition shall have the meanings assigned
to them in the Purchase Agreement.

 

WHEREAS,
Section 6.4 of the Purchase Agreement provides that the Purchase Agreement may be amended only by a written instrument signed
by the Company and the holders of at least a majority in interest of the Preferred Stock still held by all Purchasers (the “Requisite
Majority”);

 

WHEREAS,
the Lead Purchaser constitutes the Requisite Majority; and

 

WHEREAS,
the Company and the Lead Purchaser desire to amend the Purchase Agreement as set forth herein.

 

NOW,
THEREFORE, in consideration of the premises and of the mutual covenants, conditions and agreements set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending
to be legally bound, hereby agree as follows:

 

1.Amendment
of Purchase Agreement. The Purchase Agreement is hereby amended by inserting a new Section 4.14(g) as follows:

 

“(g)
Notwithstanding anything herein to the contrary, this Section 4.14 shall not apply with respect to, and no Purchaser shall have
any right to participate in, any issuance or sale of any debt securities and warrants (or the subsequent issuance of any Common
Stock or Common Stock Equivalents upon conversion or exercise thereof) by the Company that is consummated on or before June 10,
2016.”

 

2.Warrant
Transfer. In connection with the execution and delivery of this Amendment, the Lead Purchaser agrees that it will use commercially
reasonable best efforts to, as soon as reasonably practicable following the Effective Date, transfer to each Other Purchaser,
for no additional consideration, a Warrant to purchase 10,000 Warrant Shares for each share of the Company’s Series C Preferred
Stock then held by such Other Purchaser.

 

3.Effect
on Purchase Agreement. Except as specifically provided herein, the Purchase Agreement shall remain in full force and effect.

 

4.No
Third-Party Beneficiaries. This Amendment is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

5.Counterparts.
This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

6.Governing
Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York, regardless
of the laws that might otherwise govern under applicable principles of conflicts of law.

 

[Signature
Pages Follow]

 

    	 		 

     

    

 

 

[Signature
Page to Amendment to Securities Purchase Agreement]

 

IN
WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

 

	 	 
	 	COMPANY:
	 	 
	 	GUIDED THERAPEUTICS, INC.
	 	 
	 	 
	 	By: /s/ Gene S. Cartwright
	 	       Gene S. Cartwright
	 	        President and Chief Executive Officer

 

 

 

 

 

    	 		 

     

    

 

 

[Signature
Page to Amendment to Securities Purchase Agreement]

 

IN
WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

 

	 	 
	 	PURCHASER:
	 	 
	 	 
	 	AQUARIUS OPPORTUNITY FUND
	 	 
	 	 
	 	By:  EOS Investment Ltd., Its Investment Manager
	 	 
	 	 
	 	By:  /s/  Gregory Pepin
	 	        Gregory Pepin
	 	        Managing DirectorExhibit 10.12

 

ESCROW
DEPOSIT AGREEMENT

 

This
ESCROW DEPOSIT AGREEMENT (this “Agreement”) dated as of this [__] day of [_____] 2016, by and among MOLECULIN
BIOTECH, INC., a Delaware corporation (the “Company”), having an address at 2575 West Bellfort, Suite 333,
Houston, Texas 77054, BONWICK CAPITAL PARTNERS, LLC, a [ ]. (the “Underwriter”), having an address at
40 West 57th Street, 28th Floor, New York, New York 10019, and SIGNATURE BANK (the “Escrow
Agent”), a New York State chartered bank, having an office at [insert address of Signature Bank’s financial
center maintaining the account]. All capitalized terms not herein defined shall have the meaning ascribed to them in that certain
Prospectus, dated [______], 2016,including all attachments, schedules and exhibits thereto (the “Prospectus”).

 

W
I T N E S S E T H:

 

WHEREAS,
pursuant to the terms of the Memorandum the Company desires to sell (the “Offering”) a minimum of $[insert
Minimum Amount] (the “Minimum Amount”) and a maximum of $[insert Maximum Amount] (the “Maximum
Amount”) of its shares (the “Shares”). Each Share is being sold at a price of $[insert share/unit
price] per Share; and

 

WHEREAS,
unless the Minimum Amount is sold by [insert Termination Date] (the “Termination Date”), the Offering
shall terminate and all funds shall be returned to the subscribers in the Offering, and if the Minimum Amount is met, the Offering
may continue until the Termination Date; and

 

WHEREAS,
the Company and Underwriter desire to establish an escrow account with the Escrow Agent into which the Company and Underwriter
shall instruct Investors introduced to the Company by Underwriter (the “Investors”) to deposit checks and other
instruments for the payment of money made payable to the order of “Signature Bank as Escrow Agent for Moleculin Biotech,
Inc.,” and Escrow Agent is willing to accept said checks and other instruments for the payment of money in accordance with
the terms hereinafter set forth; and

 

WHEREAS,
the Company, as issuer, and Underwriter, as an introducing broker-dealer, represent and warrant to the Escrow Agent that they will
comply with all of their respective obligations under applicable state and federal securities laws and regulations with respect
to sale of the Offering; and

 

     

     

    

 

WHEREAS,
the Company and Underwriter represent and warrant to the Escrow Agent that they have not stated to any individual or entity that
the Escrow Agent’s duties will include anything other than those duties stated in this Agreement; and

 

WHEREAS,
the Company and Underwriter warrant to the Escrow Agent that a copy of each document that has been delivered to Investors
and third parties that include Escrow Agent’s name and duties, has been attached hereto as Schedule I.

  

NOW,
THEREFORE, IT IS AGREED as follows:

 

1.Delivery
of Escrow Funds.

 

(a)
Underwriter and the Company shall instruct Investors to deliver to Escrow Agent checks made payable to the order of “Signature
Bank, as Escrow Agent for Moleculin Biotech, Inc.,” or wire transfer to Signature Bank, [insert address of Signature Bank’s
financial center maintaining the account], ABA No. 026013576 for credit to Signature Bank, as Escrow Agent for Moleculin Biotech,
Inc., Account No. _____________, in each case, with the name and address of the individual or entity making payment. In the event
any Investor’s address is not provided to Escrow Agent by the Investor, then Underwriter and/or the Company agree to promptly
provide Escrow Agent with such information in writing. The checks or wire transfers shall be deposited into a non interest-bearing
account at Signature Bank entitled “Moleculin Biotech, Inc., Signature Bank, as Escrow Agent” (the “Escrow
Account”). 

 

(b)The
collected funds deposited into the Escrow Account are referred to as the “Escrow Funds.”

 

(c)The
Escrow Agent shall have no duty or responsibility to enforce the collection or demand payment of any funds deposited into the Escrow
Account. If, for any reason, any check deposited into the Escrow Account shall be returned unpaid to the Escrow Agent, the sole
duty of the Escrow Agent shall be to return the check to the Investor and advise the Company and Underwriter promptly thereof.

 

2.Release
of Escrow Funds. The Escrow Funds shall be paid by the Escrow Agent in accordance with the following:

 

(a)In
the event that the Company and Underwriter advise the Escrow Agent in writing that the Offering has been terminated (the “Termination
Notice”), the Escrow Agent shall promptly return the funds paid by each Investor to said Investor without interest or
offset.

 

     

     

    

 

(b)
Reserved.

 

(c)
Provided that the Escrow Agent does not receive the Termination Notice in accordance with Section 2(a) and there is the Minimum
Amount deposited into the Escrow Account on or prior to the Termination Date, the Escrow Agent shall, upon receipt of written instructions,
in the form of Exhibit A, attached hereto and made a part hereof, or in a form and substance satisfactory to the Escrow Agent,
received from the Company and Underwriter, pay the Escrow Funds in accordance with such written instructions, such payment or payments
to be made by wire transfer within one (1) business day of receipt of such written instructions. Such instructions must be received
by the Escrow Agent no later than 3:00 PM Eastern Time on a Banking Day for the Escrow Agent to process such instructions that
Banking Day.

 

(d)If
by 3:00 P.M. Eastern time on the Termination Date, the Escrow Agent has not received written instructions from the Company and
Underwriter regarding the disbursement of the Escrow Funds or the total amount of the Escrow Funds is less than the Minimum Amount,
then the Escrow Agent shall promptly return the Escrow Funds to the Investors without interest or offset. The Escrow Funds returned
to each Investor shall be free and clear of any and all claims of the Escrow Agent.

 

(e)The
Escrow Agent shall not be required to pay any uncollected funds or any funds that are not available for withdrawal.

 

(f)If
the Termination Date or any date that is a deadline under this Agreement for giving the Escrow Agent notice or instructions or
for the Escrow Agent to take action is not a Banking Day, then such date shall be the Banking Day that immediately preceding that
date. A “Banking Day” is any day other than a Saturday, Sunday or a day that a New York State chartered bank
is not legally obligated to be opened. 

 

3.Acceptance
by Escrow Agent. The Escrow Agent hereby accepts and agrees to perform its obligations hereunder, provided that:

 

(a)The
Escrow Agent may act in reliance upon any signature believed by it to be genuine, and may assume that any person who has been designated
by Underwriter or the Company to give any written instructions, notice or receipt, or make any statements in connection with the
provisions hereof has been duly authorized to do so. Escrow Agent shall have no duty to make inquiry as to the genuineness, accuracy
or validity of any statements or instructions or any signatures on statements or instructions. The names and true signatures of
each individual authorized to act singly on behalf of the Company and Underwriter are stated in Schedule II, which is attached
hereto and made a part hereof. The Company and Underwriter may each remove or add one or more of its authorized signers stated
on Schedule II by notifying the Escrow Agent of such change in accordance with this Agreement, which notice shall include
the true signature for any new authorized signatories.

 

     

     

    

 

(b)The
Escrow Agent may act relative hereto in reliance upon advice of counsel in reference to any matter connected herewith. The Escrow
Agent shall not be liable for any mistake of fact or error of judgment or law, or for any acts or omissions of any kind, unless
caused by its willful misconduct or gross negligence.

 

(c)Underwriter
and the Company agree to indemnify and hold the Escrow Agent harmless from and against any and all claims, losses, costs, liabilities,
damages, suits, demands, judgments or expenses (including but not limited to reasonable attorney’s fees) claimed against
or incurred by Escrow Agent arising out of or related, directly or indirectly, to this Escrow Agreement unless caused by the Escrow
Agent’s gross negligence or willful misconduct.

 

(d)In
the event that the Escrow Agent shall be uncertain as to its duties or rights hereunder, the Escrow Agent shall be entitled to
(i) refrain from taking any action other than to keep safely the Escrow Funds until it shall be directed otherwise by a court of
competent jurisdiction, or (ii) deliver the Escrow Funds to a court of competent jurisdiction.

 

(e)The
Escrow Agent shall have no duty, responsibility or obligation to interpret or enforce the terms of any agreement other than Escrow
Agent’s obligations hereunder, and the Escrow Agent shall not be required to make a request that any monies be delivered
to the Escrow Account, it being agreed that the sole duties and responsibilities of the Escrow Agent shall be to the extent not
prohibited by applicable law (i) to accept checks or other instruments for the payment of money and wire transfers delivered to
the Escrow Agent for the Escrow Account and deposit said checks and wire transfers into the non-interest bearing Escrow Account,
and (ii) to disburse or refrain from disbursing the Escrow Funds as stated above, provided that the checks received by the Escrow
Agent have been collected and are available for withdrawal.

 

     

     

    

 

4.Escrow
Account Statements and Information. The Escrow Agent agrees to send to the Company and/or the Underwriter a copy of
the Escrow Account periodic statement, upon request in accordance with the Escrow Agent’s regular practices for providing
account statements to its non-escrow clients and to also provide the Company and/or Underwriter, or their designee, upon request
other deposit account information, including Escrow Account balances, by telephone or by computer communication, to the extent
practicable. The Company and Underwriter agree to complete and sign all forms or agreements required by the Escrow Agent for that
purpose. The Company and Underwriter each consent to the Escrow Agent’s release of such Escrow Account information to any
of the individuals designated by Company or Underwriter, which designation has been signed in accordance with Section 3(a) by any
of the persons in Schedule II.  Further, the Company and Underwriter have an option to receive e-mail notification
of incoming and outgoing wire transfers. If this e-mail notification service is requested and subsequently approved by the Escrow
Agent, the Company and Underwriter agrees to provide a valid e-mail address and other information necessary to set-up this service
and sign all forms and agreements required for such service. The Company and Underwriter each consent to the Escrow Agent’s
release of wire transfer information to the designated e-mail address(es). The Escrow Agent’s liability for failure to comply
with this section shall not exceed the cost of providing such information.

 

5.Resignation
and Termination of the Escrow Agent. The Escrow Agent may resign at any time by giving 30 days’ prior written notice
of such resignation to Underwriter and the Company. Upon providing such notice, the Escrow Agent shall have no further obligation
hereunder except to hold as depositary the Escrow Funds that it receives until the end of such 30-day period. In such event, the
Escrow Agent shall not take any action, other than receiving and depositing Investors checks and wire transfers in accordance with
this Agreement, until the Company has designated a banking corporation, trust company, attorney or other person as successor. Upon
receipt of such written designation signed by Underwriter and the Company, the Escrow Agent shall promptly deliver the Escrow Funds
to such successor and shall thereafter have no further obligations hereunder. If such instructions are not received within 30 days
following the effective date of such resignation, then the Escrow Agent may deposit the Escrow Funds held by it pursuant to this
Agreement with a clerk of a court of competent jurisdiction pending the appointment of a successor. In either case provided for
in this Section, the Escrow Agent shall be relieved of all further obligations and released from all liability thereafter arising
with respect to the Escrow Funds.

 

     

     

    

 

6.Termination.
The Company and Underwriter may terminate the appointment of the Escrow Agent hereunder upon written notice specifying the date
upon which such termination shall take effect, which date shall be at least 30 days from the date of such notice. In the event
of such termination, the Company and Underwriter shall, within 30 days of such notice, appoint a successor escrow agent and the
Escrow Agent shall, upon receipt of written instructions signed by the Company and Underwriter, turn over to such successor escrow
agent all of the Escrow Funds; provided, however, that if the Company and Underwriter fail to appoint a successor
escrow agent within such 30-day period, such termination notice shall be null and void and the Escrow Agent shall continue to be
bound by all of the provisions hereof. Upon receipt of the Escrow Funds, the successor escrow agent shall become the escrow agent
hereunder and shall be bound by all of the provisions hereof and Escrow Agent shall be relieved of all further obligations and
released from all liability thereafter arising with respect to the Escrow Funds and under this Agreement.

 

7.Investment.
All funds received by the Escrow Agent shall be held only in non-interest bearing bank accounts at Signature Bank.

 

8.Compensation.
Escrow Agent shall be entitled, for the duties to be performed by it hereunder, to a fee of $4,000.00, which fee shall be paid
by the Company upon the signing of this Agreement. In addition, the Company shall be obligated to reimburse Escrow Agent for all
fees, costs and expenses incurred or that become due in connection with this Agreement or the Escrow Account, including reasonable
attorney’s fees. Neither the modification, cancellation, termination or rescission of this Agreement nor the resignation
or termination of the Escrow Agent shall affect the right of Escrow Agent to retain the amount of any fee which has been paid,
or to be reimbursed or paid any amount which has been incurred or becomes due, prior to the effective date of any such modification,
cancellation, termination, resignation or rescission. To the extent the Escrow Agent has incurred any such expenses, or any such
fee becomes due, prior to any closing, the Escrow Agent shall advise the Company and the Company shall direct all such amounts
to be paid directly at any such closing.

 

     

     

    

 

9.Notices.
All notices, requests, demands and other communications required or permitted to be given hereunder shall be in writing and shall
be deemed to have been duly given if sent by hand-delivery, by facsimile (followed by first-class mail), by nationally recognized
overnight courier service or by prepaid registered or certified mail, return receipt requested, to the addresses set forth below:

 

If
to Underwriter:

 

Bonwick
Capital Partners, LLC

40
West 57th Street, 28th Floor

New
York, New York 10019

Attention:
Daniel J. McClory, Managing Director

Fax:

 

If
to the Company:

 

Moleculin
Biotech, Inc.

2575
West Bellfort, Suite 333

Houston,
Texas 77054

Attention:
Walter V. Klemp, Acting CEO

 

If
to Escrow Agent:

 

Signature
Bank

[address
of financial center]

_______________

Attention:
[name & title of Group Director]

Fax:
[Private Client Group’s fax number]

 

10.General.

 

(a)This
Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York applicable to agreements
made and to be entirely performed within such State, without regard to choice of law principles and any action brought hereunder
shall be brought in the courts of the State of New York, located in the County of New York. Each party hereto irrevocably waives
any objection on the grounds of venue, forum nonconveniens or any similar grounds and irrevocably consents to service of process
by mail or in any manner permitted by applicable law and consents to the jurisdiction of said courts. EACH OF THE PARTIES HERETO
HEREBY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF THE TRANSACTIONS CONTEMPLATED
BY THIS AGREEMENT.

 

     

     

    

 

(b)This
Agreement sets forth the entire
agreement and understanding of the parties with respect to the matters contained herein and supersedes all prior agreements, arrangements
and understandings relating thereto.

 

(c)All
of the terms and conditions of this Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the parties
hereto, as well as their respective successors and assigns.

 

(d)This
Agreement may be amended, modified, superseded or canceled, and any of the terms or conditions hereof may be waived, only by a
written instrument executed by each party hereto or, in the case of a waiver, by the party waiving compliance. The failure of any
party at any time or times to require performance of any provision hereof shall in no manner affect its right at a later time to
enforce the same. No waiver of any party of any condition, or of the breach of any term contained in this Agreement, whether by
conduct or otherwise, in any one or more instances shall be deemed to be or construed as a further or continuing waiver of any
such condition or breach or a waiver of any other condition or of the breach of any other term of this Agreement. No party may
assign any rights, duties or obligations hereunder unless all other parties have given their prior written consent.

 

(e)If
any provision included in this Agreement proves to be invalid or unenforceable, it shall not affect the validity of the remaining
provisions.

 

(f)This
Agreement and any modification or amendment of this Agreement may be executed in several counterparts or by separate instruments
and all of such counterparts and instruments shall constitute one agreement, binding on all of the parties hereto.

 

11.Form
of Signature. The parties hereto agree to accept a facsimile transmission copy of their respective actual signatures as evidence
of their actual signatures to this Agreement and any modification or amendment of this Agreement; provided, however,
that each party who produces a facsimile signature agrees, by the express terms hereof, to place, promptly after transmission of
his or her signature by fax, a true and correct original copy of his or her signature in overnight mail to the address of the other
party.

 

12.
No Third-Party Beneficiaries.  This Agreement is solely for the benefit of the parties and their respective
successors and permitted assigns, and no other person has any right, benefit, priority, or interest under or because of the existence
of this Agreement.

 

     

     

    

 

 

IN
WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first set forth above.

 

	MOLECULIN BIOTECH, INC.	 	BONWICK CAPITAL PARTNERS, LLC	 
	 	 	 	 	 	 	 
	BY:	 	 	BY:	 	 
	 	NAME:	WALTER V. KLEMP	 	 	NAME:   	 
	 	TITLE:	ACTING CHIEF EXECUTIVE OFFICER	 	 	TITLE:   	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	SIGNATURE BANK	 	 	 	 
	 	 	 	 	 
	BY:	 	 	 	 	 
	 	NAME:	 	 	 	 	 
	 	TITLE:	 	 	 	 	 
	 	 	 	 	 	 	 
	BY:	 	 	 	 	 
	 	NAME:	 	 	 	 	 
	 	TITLE:	 	 	 	 	 

 

 

 

     

     

    

Schedule
I

 

OFFERING
DOCUMENTS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	Escrow Deposit Agreement – Public Offering	Rev. 05/2015

 

     

     

    

Schedule
II

 

The
Escrow Agent is authorized to accept instructions signed or believed by the Escrow Agent to be signed by any one of the following
on behalf of the Company and Underwriter. 

 

 

 

Moleculin
Biotech, Inc.

 

 

	 	Name	 	True Signature	 
	 	 	 	 	 
	 	 	 	 	 
	 	Walter V. Klemp	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	Louis Ploth, Jr.	 	 	 
	 	 	 	 	 

 

Bonwick
Capital Partners, LLC 

	 	 	 	 	 
	 	 	 	 	 
	 	Name	 	True Signature	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

 

 

 

 

 

 

 

 

	Escrow Deposit Agreement – Public Offering	Rev. 05/2015

 

     

     

    

Exhibit
A

 

FORM
OF ESCROW RELEASE NOTICE

 

Date:

 

Signature
Bank

[address of financial
center]

______________

Attention:
[name & title of Group Director]

 

Dear
_________:

 

In
accordance with the terms of Section 2(c) of an Escrow Deposit Agreement dated as of ________ __, 2016 (the "Escrow Agreement"),
by and between Moleculin Biotech, Inc. (the "Company"), Signature Bank (the "Escrow Agent") and Bonwick Capital
Partners, LLC. ("Underwriter"), the Company and Underwriter hereby notify the Escrow Agent that the ________ closing
will be held on ___________ for gross proceeds of $_________.

 

 

PLEASE
DISTRIBUTE FUNDS BY WIRE TRANSFER AS FOLLOWS (wire instructions attached):

 

 

________________________:$

 

________________________:$
 

 

________________________:$

 

 

Very truly yours,

 

Moleculin
Biotech, Inc.

 

By:_____________

Name:__________

Title:____________

 

Bonwick Capital Partners,
LLC

 

By:_____________

Name:___________

Title:____________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]